The pooled ORs showed significantly lower rates of any grade adverse events in the anti-PD-1/PD-L1 groups than in the docetaxel groups, including alopecia (OR = 0.01, 95% CI 0.01–0.02), fatigue (OR = 0.54, 95% CI 0.46–0.63), nausea (OR = 0.52, 95% CI 0.39–0.70), diarrhea (OR = 0.36, 95% CI 0.27–0.49), anemia (OR = 0.21, 95% CI 0.12–0.37), decreased appetite (OR = 0.78, 95% CI 0.60–1.00), and neutropenia (OR = 0.04, 95% CI 0.02–0.06) (Table 4, Supplementary Figures). The gene discussed is CD274; the disease is anemia (phenotype).